Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast Cancer

Video

In Partnership With:

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses adding phosphoprotein testing to genomic testing for patients with breast cancer.

O’Shaughnessy explains she has often used phosphoprotein analyses in order to determine driving mutations in refractory tumors. For example, she mentions a patient with refractory triple-negative breast cancer who, upon genomic analysis, had several mutational abnormalities. Therefore, a clear treatment plan could not be determined. However, by using a phosphoprotein assay, fibroglast growth factor receptor was found to be the single driving mutation.

This is helpful, O’Shaughnessy says, because several mutational abnormalities may act as passengers and/or are inactive in patients, and the driving mutation may not be determined solely with a genomic analysis.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD